Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Mar 11, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Transformed Lymphoma.

Mary Ann Anderson¹, Piers Blombery², John F Seymour³

¹Cancer and Haematology Division, Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville 3050, Australia; Department of Clinical Hematology and Bone Marrow Transplantation, The Royal Melbourne Hospital, Parkville 3050, Australia.

Hematology/Oncology Clinics of North America

|November 28, 2016

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE study.

HemaSphere·2026

Same author

Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.

The Lancet. Haematology·2026

Same author

Impact of peri-transplant consolidative radiotherapy in patients with relapsed or refractory classical Hodgkin lymphoma.

Leukemia & lymphoma·2026

Same author

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Blood·2026

Same author

Marginal Zone Lymphoma: 2026 Update on Diagnosis and Management.

American journal of hematology·2026

Same author

Venetoclax retreatment in chronic lymphocytic leukemia is biologically rational and clinically effective.

Blood advances·2026

Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026

Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026

Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026

Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026

Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026

Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026

See all related articles

Transformed lymphoma involves low-grade conditions becoming aggressive. Understanding genetic drivers is key to developing targeted therapies for chronic lymphocytic leukemia and follicular lymphoma transformation.

Area of Science:

Hematology
Oncology
Genetics

Background:

Transformed lymphoma represents the progression of indolent lymphoproliferative disorders to aggressive malignancies.
Morphologic, clinical, and genetic shifts characterize this transformation process.
Recent chemoimmunotherapy advancements offer new treatment avenues.

Purpose of the Study:

To review the transformation of chronic lymphocytic leukemia and follicular lymphoma into diffuse large B-cell lymphoma.
To highlight the role of genetic alterations in lymphoma transformation.
To discuss emerging targeted therapies based on genetic insights.

Main Methods:

Literature review of transformed lymphoma, focusing on chronic lymphocytic leukemia and follicular lymphoma.

Keywords:

Genetic drivers Indolent lymphoma Transformed lymphoma

More Related Videos

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

A Simple Red Blood Cell Lysis Method for the Establishment of B Lymphoblastoid Cell Lines

A Simple Red Blood Cell Lysis Method for the Establishment of B Lymphoblastoid Cell Lines

Published on: January 14, 2017

Related Experiment Videos

Last Updated: Mar 11, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

A Simple Red Blood Cell Lysis Method for the Establishment of B Lymphoblastoid Cell Lines

A Simple Red Blood Cell Lysis Method for the Establishment of B Lymphoblastoid Cell Lines

Published on: January 14, 2017

Analysis of genetic drivers of transformation.

Discussion of current and novel therapeutic strategies.

Main Results:

Genetic changes are crucial in the evolution from low-grade to high-grade lymphomas.
Targeted therapies are being developed based on specific genetic mutations.
Chemoimmunotherapy remains a cornerstone, with targeted agents offering new hope.

Conclusions:

Understanding the genetic landscape of lymphoma transformation is critical for therapeutic development.
Novel targeted therapies hold promise for improving outcomes in transformed lymphomas.
Further research into genetic drivers will refine treatment strategies for these aggressive diseases.